

Tejaswini Kulkarni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4431419/publications.pdf>

Version: 2024-02-01

33
papers

767
citations

623734

14
h-index

552781

26
g-index

33
all docs

33
docs citations

33
times ranked

1593
citing authors

#	ARTICLE	IF	CITATIONS
1	Matrix Remodeling in Pulmonary Fibrosis and Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 751-760.	2.9	97
2	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
3	Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis. Journal of Immunology, 2017, 199, 1596-1605.	0.8	76
4	Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L280-L292.	2.9	62
5	Citrullinated vimentin mediates development and progression of lung fibrosis. Science Translational Medicine, 2021, 13, .	12.4	60
6	Alveolar epithelial disintegrity in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L185-L191.	2.9	52
7	Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insight, 2020, 5, .	5.0	39
8	Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L141-L154.	2.9	37
9	Loss of Salmeterol Bronchoprotection against Exercise in Relation to ADRB2 Arg16Gly Polymorphism and Exhaled Nitric Oxide. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1407-1412.	5.6	35
10	Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS ONE, 2019, 14, e0221905.	2.5	31
11	Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 861-868.	5.6	30
12	Extracorporeal membrane oxygenation in adults: A practical guide for internists. Cleveland Clinic Journal of Medicine, 2016, 83, 373-384.	1.3	27
13	Update in Pulmonary Fibrosis 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 292-300.	5.6	23
14	Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L928-L940.	2.9	19
15	Heme Oxygenase-1 Protects Corexit 9500A-Induced Respiratory Epithelial Injury across Species. PLoS ONE, 2015, 10, e0122275.	2.5	15
16	Preoperative Evaluation of Patients With Interstitial Lung Disease. Chest, 2019, 156, 826-833.	0.8	13
17	The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. Respiratory Medicine, 2020, 161, 105821.	2.9	12
18	A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respiratory Medicine, 2016, 115, 33-38.	2.9	11

#	ARTICLE	IF	CITATIONS
19	Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations. PLoS ONE, 2021, 16, e0260345.	2.5	10
20	Flexible Bronchoscopy Is Safe and Effective in Adult Subjects Supported With Extracorporeal Membrane Oxygenation. Respiratory Care, 2016, 61, 646-651.	1.6	7
21	Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat. Current Pulmonology Reports, 2019, 8, 123-130.	1.3	7
22	Top Ten Tips Palliative Care Clinicians Should Know About Prognostication in Oncology, Dementia, Frailty, and Pulmonary Diseases. Journal of Palliative Medicine, 2021, 24, 1391-1397.	1.1	6
23	Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. Respiratory Medicine, 2021, 189, 106637.	2.9	4
24	Cost of Hospitalization Among Patients With Idiopathic Pulmonary Fibrosis: Patterns and Predictors. Chest, 2016, 150, 469A.	0.8	2
25	The Impact of Comorbidities on Idiopathic Pulmonary Fibrosis Outcomes. Chest, 2016, 150, 471A.	0.8	1
26	Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respiratory Research, 2022, 23, 3.	3.6	1
27	Extracorporeal Membrane Oxygenation in Obstructive Lung Diseases Refractory to Conventional Therapy. Chest, 2015, 148, 323A.	0.8	0
28	Safety of Flexible Bronchoscopy in Critically ill Adult Patients Supported With Extracorporeal Membrane Oxygenation. Chest, 2015, 148, 290A.	0.8	0
29	WHERE THERE IS NOT SMOKE THERE IS STILL FIRE: A CASE OF PULMONARY LANGERHANS CELL HISTIOCYTOSIS IN A FORMER SMOKER WITH A HISTORY OF MULTIPLE MALIGNANCIES. Chest, 2019, 156, A188.	0.8	0
30	NATURAL HISTORY OF INTERSTITIAL LUNG DISEASE (ILD) AND RESPONSE TO TREATMENT REGIMENS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM): A SINGLE CENTER EXPERIENCE. Chest, 2020, 158, A1046-A1047.	0.8	0
31	A HIDDEN DIAGNOSIS MANIFESTING AS NONSPECIFIC INTERSTITIAL PNEUMONIA: IGG4-RELATED LUNG DISEASE. Chest, 2020, 158, A2010-A2011.	0.8	0
32	Characteristics of Patients With Pulmonary Venocclusive Disease Awaiting Transplantation: Comparison With Pulmonary Arterial Hypertension Patients. Chest, 2014, 146, 975A.	0.8	0
33	Nintedanib—A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease. US Respiratory & Pulmonary Diseases, 2020, 5, 28.	0.2	0